Phenotypic screening is experiencing a Renaissance in the pharmaceutical industry, based on its successful track record in delivering first-in-class medicines stemming from novel biology. Although phenotypic screening may appear at first sight to be similar to target-based screening, there are some fundamental differences between the two approaches. This course will deliver a theoretical and practical framework for the use of phenotypic drug discovery by (1) providing a broad context of the drug discovery process, (2) comparing and contrasting molecular target driven and empirical phenotypic drug discovery strategies, (3) providing guidelines on why and when to utilize an empirical phenotypic drug discovery approach and (4) providing practical information to prosecute phenotypic programs more effectively.
Who Should Attend: • Academic scientists considering or using phenotypic screens to discover novel biology and molecular probes. • Industry scientists considering or using phenotypic screens to discover novel targets and clinical candidates. • Commercial providers of reagents, instruments and services used in phenotypic screening. • Attendees will participate in an active dialogue with instructors and other participants on course topics. “Phenotypic Screening: Why, When and How” is not a typical “how to” course, since no clear cut “one size fits all” strategy exists for an endeavor as complex as drug discovery.
How You Will Benefit From This Course? Attendees will leave this course with: • A high level overview of the drug discovery and development process. • An overview of Pharma productivity with potential technical reasons for poor productivity. • An understanding of the pros and cons associated with hypothesis driven and empirical drug discovery. • Practical knowledge of key concepts and strategies in phenotypic screening supported by case studies and literature references to bring back to their organizations.
Course Topics: Morning Session: 1. Overview of Pharma R&D productivity 2. Overview of the drug discovery and development process: Unmet medical need to registration 3. Relating R&D poor productivity to drug discovery strategies 4. Target-based & Phenotypic Drug Discovery strategies: first in class & best in class 5. Choosing a screening strategy: multi-dimensional risk management Afternoon Session: 1. Not all phenotypic assays are created equal: what are the characteristics of the best assays? 2. Which libraries should be screened and why? Small molecule and/or genetic screening? 3. What are key considerations and strategies for phenotypic screening hit triage and validation? 4. What are key considerations and strategies for target/mechanism identification and validation? 5. What are key considerations and strategies for phenotypic program progression?